119-HR-3164 DC Insider Whip Count Analysis

Where the bill stands

- Vehicle: H.R. 3164 ("Ensuring Community Access to Pharmacist Services Act") was amended and ordered favorably reported by House Ways & Means on May 21, 2026; the chair’s ANS renames it the "Main Street Pharmacy Access Act," removes the 100% PHE payment bump, moves the effective date to January 1, 2028, and offsets costs by zeroing out the Medicare Improvement Fund. [1]U.S. House Committee on Ways and Means — Markup of H.R. 3164 – Ways & Means (Ma… - Companion: S. 2426 (ECAPS) is sponsored by Senate Majority Leader John Thune and was referred to Senate Finance. [2]Congress.gov (Library of Congress) — S.2426 — Equitable Community Access to Pha… - Institutional context: Republicans control both chambers; Thune leads the Senate and Mike Johnson is the House Speaker. [3]U.S. Senate — Senate Majority and Minority Leaders — 119th Congress

• Scope: The bill would allow Medicare Part B payment for specified pharmacist E/M services for COVID‑19, influenza, RSV, and strep, plus limited PHE‑related conditions, consistent with state scope and collaboration rules. [4]Congress.gov (Library of Congress) — H.R.3164 — Ensuring Community Access to Ph…
• Jurisdiction: House Energy & Commerce and Ways & Means; Senate Finance. [4]Congress.gov (Library of Congress) — H.R.3164 — Ensuring Community Access to Ph…
• Support coalition: AMCP, ASHP, NACDS and others publicly backed committee advancement on May 21, 2026. [5]AMCP — AMCP press release: Commends advancement of Main Street Pharmacy Access…
• Organized opposition: AMA and allied physician groups oppose ECAPS/ECAPS‑equivalent language on scope‑of‑practice and safety grounds. [6]American Medical Association — AMA: Physician‑led care is best — position oppos…

Breakdown: expected support and opposition

Expect a broadly bipartisan, pharmacy‑friendly coalition in the House, narrower but still cross‑party support in the Senate, with resistance clustered among physician‑aligned members and committees sensitive to scope‑of‑practice fights. [5]AMCP — AMCP press release: Commends advancement of Main Street Pharmacy Access…

Notes: Congress.gov shows roughly 100 bipartisan House cosponsors; exact count fluctuates with updates. Expect floor managers to emphasize the narrowed scope and 2028 start date to contain costs and address medical‑society concerns. [4]Congress.gov (Library of Congress) — H.R.3164 — Ensuring Community Access to Ph…

Key legislators to watch

These members shape the bill’s path and the bargaining space.

• Rep. Adrian Smith (R‑NE) — sponsor; his office is already messaging W&M passage. Expect him to manage floor strategy with leadership. [8]Office of Rep. Adrian Smith — Rep. Adrian Smith press release: W&M passes Main…
• Chair Jason Smith (R‑MO), Ways & Means — ran the markup; ANS rename and pay‑for choices came through his desk. [1]U.S. House Committee on Ways and Means — Markup of H.R. 3164 – Ways & Means (Ma…
• Chair Brett Guthrie (R‑KY), Energy & Commerce — E&C will likely clear remaining jurisdictional equities; his chairmanship matters for any technical alignment with Food/Drug and Medicare provisions. [9]energycommerce.house.gov
• Speaker Mike Johnson (R‑LA) and Majority Leader Steve Scalise (R‑LA) — control House floor time and whether to use suspension or a rule. [10]U.S. House Radio–Television Gallery — House Republican Leadership, 119th Congre…
• Sen. John Thune (R‑SD), Majority Leader — lead Senate sponsor; can prioritize floor time if Finance reports. [2]Congress.gov (Library of Congress) — S.2426 — Equitable Community Access to Pha…
• Sen. Mike Crapo (R‑ID), Finance Chair — gatekeeper for hearings/markup; will weigh offsets and scope language. [11]U.S. Senate Committee on Finance — Crapo named Chairman of Senate Finance Commi…
• Sen. Mark Warner (D‑VA) — Democratic co‑lead; key for building a 60‑vote coalition or inclusion in a year‑end package. [2]Congress.gov (Library of Congress) — S.2426 — Equitable Community Access to Pha…
• Medical‑profession senators (e.g., Sens. Paul, Marshall, Cassidy, Barrasso) — not publicly declared here but traditionally sensitive on scope debates; watch for guardrail amendments. (Opposition letters from AMA/AOA frame their likely asks.) [6]American Medical Association — AMA: Physician‑led care is best — position oppos…

Leadership influence and procedural dynamics

Path of least resistance: move H.R. 3164 under suspension in the House with broad bipartisan votes; in the Senate, either assemble 60 or fold into a year‑end health “extenders” package.

• House options: Suspension of the rules (two‑thirds required) or a special rule; W&M’s voice‑vote report and bipartisan cosponsors make suspension plausible if leadership wants speed. [12]Congressional Research Service — CRS In Focus: Suspension of the Rules in the H…
• What changed in markup: The ANS rebrands the bill, clarifies E/M coding, removes the temporary 100% PHE payment, delays the start date to 2028, and pays for it by rescinding the Medicare Improvement Fund — all choices that reduce CBO friction. [13]U.S. House Committee on Ways and Means — H.R. 3164 Green Sheet — Chairman’s Ame…
• Senate math: Absent reconciliation eligibility, ordinary legislation must clear cloture (three‑fifths/60). Thune’s sponsorship helps, but physician‑group opposition raises the bar for a standalone floor run. [14]Congressional Research Service (hosted by FAS) — CRS: Filibusters and Cloture i…
• Alternate Senate path: Attach to a year‑end health package alongside routine Medicare/Medicaid “extenders,” a common practice that can carry smaller bipartisan items. [15]American Action Forum — Health care extenders in the Consolidated Appropriation…
• Committee terrain: Senate Finance (Crapo/Wyden) controls the next moves; House E&C retains equities tied to Medicare Part B scope and public‑health authorities. [2]Congress.gov (Library of Congress) — S.2426 — Equitable Community Access to Pha…

Assessment: likely support and passage odds

Bottom line: this is a classic bipartisan access bill, now fiscally tightened. House is set up for passage; Senate viability depends on coalition management or a catch‑ride on must‑pass health legislation.

• House: Likely to pass (high confidence). W&M voice‑vote report, strong pharmacy coalition, and narrowed ANS ease concerns and make suspension viable. [1]U.S. House Committee on Ways and Means — Markup of H.R. 3164 – Ways & Means (Ma…
• Senate: Toss‑up to lean‑yes (moderate confidence). Leadership backing (Thune) is a tailwind; organized physician opposition and 60‑vote friction are the headwinds. Watch Finance scheduling and year‑end packaging signals. [2]Congress.gov (Library of Congress) — S.2426 — Equitable Community Access to Pha…
• Overall: Moderate likelihood this Congress, with the cleanest path via inclusion in a late‑2026 health extenders title. [15]American Action Forum — Health care extenders in the Consolidated Appropriation…